Cargando…
Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?
BACKGROUND: Pharmacological corticosteroid therapy is the standard of care in Duchenne Muscular Dystrophy (DMD) that aims to control symptoms and slow disease progression through potent anti-inflammatory action. However, a major concern is the significant adverse effects associated with long term-us...
Autores principales: | Kourakis, Stephanie, Timpani, Cara A., Campelj, Dean G., Hafner, Patricia, Gueven, Nuri, Fischer, Dirk, Rybalka, Emma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934375/ https://www.ncbi.nlm.nih.gov/pubmed/33663533 http://dx.doi.org/10.1186/s13023-021-01758-9 |
Ejemplares similares
-
Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy
por: Kourakis, Stephanie, et al.
Publicado: (2020) -
Adenylosuccinic acid therapy ameliorates murine Duchenne Muscular Dystrophy
por: Timpani, Cara A., et al.
Publicado: (2020) -
The Failed Clinical Story of Myostatin Inhibitors against Duchenne Muscular Dystrophy: Exploring the Biology behind the Battle
por: Rybalka, Emma, et al.
Publicado: (2020) -
Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go?
por: Timpani, Cara A., et al.
Publicado: (2020) -
Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy
por: Timpani, Cara A., et al.
Publicado: (2017)